Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

40.37 +0.62 (+1.55%)
Streaming Delayed Price Updated: 11:56 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody... 
Via Talk Markets
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
From Legend Biotech Corporation
Via Business Wire
Key Takeaways From Legend Biotech Analyst Ratings
Via Benzinga
Analyst Ratings for Legend Biotech
Via Benzinga
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments. 
Via Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
The Latest Analyst Ratings for Legend Biotech
Via Benzinga
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
Earnings Scheduled For November 20, 2023
Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million. 
Via Benzinga
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. 
Via The Motley Fool
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
From Legend Biotech Corporation
Via Business Wire
Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug
Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,  
Via Benzinga
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
3 Biotech Stocks That Analysts Are Drooling Over
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
From Legend Biotech Corporation
Via Business Wire
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.